Login to Your Account

SEEKing a Partner

Universal Flu Vaccine Developer Reports Good Phase II Data

By Nuala Moran
BioWorld International Correspondent

Wednesday, November 9, 2011
LONDON – SEEK Ltd. released Phase II results of a challenge trial of its T-cell vaccine FLU-v against influenza, showing healthy volunteers who were vaccinated had less severe symptoms, over a shorter time, than the controls.

To continue reading subscribe now to BioWorld Asia (formerly International)

Learn More about BioWorld Asia (formerly International)

Already a subscriber? Sign In or Buy now to activate your subscription